Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Total Liabilities (2019 - 2025)

Historic Total Liabilities for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $26.4 million.

  • aTYR PHARMA's Total Liabilities fell 22.66% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year decrease of 22.66%. This contributed to the annual value of $26.8 million for FY2024, which is 1061.51% down from last year.
  • Latest data reveals that aTYR PHARMA reported Total Liabilities of $26.4 million as of Q3 2025, which was down 22.66% from $26.7 million recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's Total Liabilities ranged from a high of $30.0 million in Q4 2023 and a low of $5.4 million during Q1 2021
  • Moreover, its 5-year median value for Total Liabilities was $24.5 million (2024), whereas its average is $19.9 million.
  • In the last 5 years, aTYR PHARMA's Total Liabilities plummeted by 5595.42% in 2021 and then soared by 32393.0% in 2023.
  • aTYR PHARMA's Total Liabilities (Quarter) stood at $6.4 million in 2021, then surged by 282.19% to $24.5 million in 2022, then rose by 22.42% to $30.0 million in 2023, then decreased by 10.62% to $26.8 million in 2024, then decreased by 1.47% to $26.4 million in 2025.
  • Its Total Liabilities stands at $26.4 million for Q3 2025, versus $26.7 million for Q2 2025 and $22.2 million for Q1 2025.